Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMP-131R10 + FOLFIRI
- Development stage
- Unknown
- Lead developer
- Mereo BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
OMP-131R10 + FOLFIRI is a **combination investigational therapy** comprising OMP-131R10 (rosmantuzumab), a humanized monoclonal antibody targeting R-spondin 3 (RSPO3), and the FOLFIRI chemotherapy regimen (folinic acid, fluorouracil, irinotecan)[2][3][4][5][8]. OMP-131R10 inhibits the R-spondin–LGR pathway, a key regulator of the Wnt signaling involved in cancer stem cell renewal and tumor growth, with potential antineoplastic activity, particularly in metastatic colorectal cancer. FOLFIRI acts through cytotoxic mechanisms targeting rapidly dividing cells. This combination aims to enhance anti-tumor efficacy by attacking cancer cells both through conventional cytotoxic chemotherapy and targeted disruption of cancer stem cell/Wnt signaling pathways[2][3][4][5][8].
- Other names
- anti-RSPO3 antibody + FOLFIRIrosmantuzumab + FOLFIRI
02
Targets
TOP1 (DNA Topoisomerase I)RSPO3 (R-spondin 3)TS (Thymidylate synthase)
Beyond the preview
Go deeper on OMP-131R10 + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMP-131R10 + FOLFIRI.